Antibody-Targeting of Tumour-Associated Carbohydrate Antigens (TACAs) for Passive Immunotherapies

Time: 1:30 pm
day: Day Two


  • Presenting TACAs as a novel class of targets exclusively expressed on tumour cells
  • Uncovering how TACAs drive tumour progression by mediating metastasis, induction of angiogenesis or down-modulation of the immune system and therefore are ideal targets to interfere with tumour progression and targeting for antibody-mediated cell killing
  • Outlining Tacalyx’s technology which allows the generation and characterisation of specific antibodies suitable for clinical development